Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
highlighted for everyone to see. huge news
Huge News Today !!! To Build a 300 MW Thermal Coal Power Plant Near their Coal Property in Colombia
BARRANQUILLA, Colombia, October 19, 2016 /PRNewswire/ --
Metallurgical Coal prices continue to surge, up over 300% this year to over $ 230/tonne
New Colombia Resources, Inc. (NEWC) ("New Colombia or the 'Company"), a Colombian resource company listed in the U.S. with premium metallurgical coal mining titles and medical marijuana subsidiaries is pleased to report on the status of a project to build a thermal coal power plant in Guaduas, Colombia. Company subsidiary, Compañía Minera San Jose Ltda. entered into negotiations earlier this year with a foreign entity to build a 300 Megawatt thermal coal power plant near their estimated vast coal reserves. This entity has secured a Letter of Intent for US$ 200 Million from a major construction company in China to join a consortium to finance the development of the coal operations to feed this new plant and construction of the power plant.
New Colombia Resources' Director, Erasmo Almanza, received a report from the consortium partner on the status of negotiations of the installation of the thermal coal power plant in Guaduas. The report states there have been meetings with the financing team seeking the best financing option for the project and have modified the volume of power generation to optimize material inventory with time. A decision was made to program a meeting with Mr. Almanza after these adjustments are finalized to protocolize the negotiations and establish the new power company.
Guaduas is located 110 Km northeast of the capital of Bogota with an estimated 10 Million people. Colombia's energy generation is dominated by hydro-electric which causes concerns during droughts and a weather phenomenon.
The Company's coal reserves are estimated to be 70% metallurgical and 30% thermal, for a comprehensive estimate of probable reserves on their first concession contract ILE-09551 visit http://www.newcolombiaresources.com/assesment.php
The concession contract to be developed by the consortium is in close proximity to Concession Contract ILE-09551 and expected to have a similar 70/30 ratio of coking coal to thermal coal.
The Company feels this is a major development creating a local market for their thermal coal while developing metallurgical coking coal that has more than tripled in price this year to over $ 230/tonne. Additionally, the Company has met with a multi-billion-dollar Asian conglomerate interested in their premium metallurgical coal.
.
Goldman Sachs issued a report stating their projection that coking coal prices will remain high. http://www.bloomberg.com/news/articles/2016-09-23/goldman-says-higher-coking-coal-prices-are-here-to-stay
Shares in big board metallurgical coal producers like BHP Billiton (BHP), Consol Energy Inc. (CNX), and Cloud Peak Energy Inc. (NYSE:CLP) have seen significant price increases in the past few weeks.
Additionally, Company attorney is drafting an SEC Form 8K to address the elimination of debt that was recently being converted into free trading shares.
New Colombia Resources' Blue Gem coal is only found on the KY-TN border and central Colombia and is used to produce specialty metals such as Silicone to make solar panels, electric car batteries, and many more next generation products. New Colombia Resources has concession contracts and applications totaling 5000 HA of high quality metallurgical coal that will always be needed to produce steel and other specialty metallurgy products. Blue Gem coal miners in Kentucky are shutting down operations due to over-regulation creating a supply void the Company intends to fill.
New Colombia Resource also has a joint venture manufacturing medical marijuana products and is in the process of creating sustainable hemp industries in Colombia. To view or purchase Sannabis products visit http://www.sannabis.co. Follow Sannabis on Facebook for photos and testimonials at https://www.facebook.com/sannabis.cannamedicinal
New Colombia Resources, Inc.
New Colombia Resources, Inc. is focused on the acquisition and development of high-quality metallurgical coal properties and other available resources in the Republic of Colombia. They expect to have several revenue producing businesses including; metallurgical coal mining and rock quarry aggregates for domestic Colombian highway and railroad building projects. The Company owns 100% of La Tabaquera metallurgical coal mine in Colombia with an estimated 15- 17 million tonnes of reserves. They have another pending acquisition for 390 ha and a solicitation contract for 184 ha metallurgical coal concession. New Colombia Resources also holds a significant position in Sannabis SAS which legally produces medical marijuana products in the Republic of Colombia, visit http://www.sannabis.co. For more information on the Company visit http://www.newcolombiaresources.com.
Link :http://finance.yahoo.com/news/colombia-resources-negotiations-build-300-143200002.html
ABCO ENERGY, INC. ANNOUNCES SIGNING OF LIGHTING
CONTRACTS
TUCSON, AZ – October 14, 2016, ABCO Energy, Inc., (OTCQB: “ABCE”) announced signing of a
significant LED lighting project with a national company that specializes in shaded parking at international
airports in the United States. The customer operates large parking properties at 17 major airports and is
growing rapidly. ABCO is the only energy efficient lighting vendor they are using at this time.
ABCO will provide in excess of 1,000 lighting fixtures in the first contract and has opportunities for all
parking facilities in the near future.
ABCO hired Mr. Paul d’Hedouville, a long term marketing and international business development
specialist, from Washington DC, to head up the “ABCO Commercial Lighting” division. His assignment
has been to attract national and multi-location firms that will benefit from energy savings. This technology
may save up to 70% of the customer’s electric costs for lighting and significantly reduces cooling and
replacement costs.
“Paul’s first accomplishment with a national firm is very encouraging for the company. National multilocation
firms often provide sales for many years on a repeat basis. We also know that solar installations
normally follow the lighting contracts. In addition, Paul has sold an additional five contracts, one to a
multi-location dry cleaning establishment that will put our lighting in several locations here in Tucson. We
are pleased to see the LED Commercial Lighting division standing on its own at such an early stage in
Paul’s employment” says Charles O’Dowd, President of ABCO Energy.
ABCO Energy, Inc. is an Arizona licensed contractor for sales and installation of Photovoltaic Solar
Systems, Solar Street Lighting and installation of LED and energy conservation lighting systems in their
markets. ABCO provides products and services to residential, commercial, government and non-profit
entities in all of their markets.
Link: http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=22419
OTC Markets states Float: 58,004,390 a/o Jul 11, 2016
http://www.otcmarkets.com/stock/GBHL/profile
What is the most current float?
I found this in the fillings. June 30 2016
Shares held by Insiders :58,269,219 - 43.13%
Shares held by Other : 76,842,877 - 56.87%
Total Shares : 135,112,096 - 100.00%
link: http://www.otcmarkets.com/financialReportViewer?symbol=GBHL&id=158203
Morning Star pattern formed Friday.
Millennial's shares are now listed for trading on the OTCQB markets in the United States under the symbol MLNLF
took starter at 1
in at 36
well said
If all goes well.
-Earning 3% royalties from several worldwide distributors for the Psoriasis cream. to help fund research in:
-Finished trials for the Multiple myeloma on mice duplicating results of in-vitro or better - 100% malignant cell death in 60% of cases.
- Started clinical trials, in-vitro fibromyalgia study.
- not to mention advancement on PTSD trials
- Migrain tablets (specific formulations of CBD and THC tablets absorbed thru cheeks)
- several other patents they can research in including Special formulated Condoms to treat ED.
God times ahead for OWCP.
Just my opinion.
Working on getting the cream out there and establishing steady royalty streams. Huge market in the US alone. Legalizing MJ is going on all over. Our PM was elected with the intent of legalizing it here in Canada.
Nice, gonna get lots more eyes on this as we get closer to election.
sales and marketing both in Israel the US in the second quarter of 2017, of the topical crème compound for the treatment of psoriasis and related skin conditions, and have already been in contact with a number of representatives who have expressed interest in manufacturing and distributing the crème in their state. ( I wonder if they mean state as a country ? )
Link http://www.cnbc.com/2016/10/11/pr-newswire-owc-pharmaceutical-research-corp-to-initiate-efficacy-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. OWCP is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
Link to final cream phase http://www.cnbc.com/2016/10/11/pr-newswire-owc-pharmaceutical-research-corp-to-initiate-efficacy-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html
On CNBC site, sweet
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. OWCP is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
Link to final cream phase http://www.cnbc.com/2016/10/11/pr-newswire-owc-pharmaceutical-research-corp-to-initiate-efficacy-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
Link to cream final phase http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125710148
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
wow a big 39 share sell on bid lol
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
now watch peeps chase as we go back up
yeah loading look at l2 bids lol.
lol, still loading...
yeah this is great got me some more in high 3's.
wow got some nice fills thank you for selling
Quotes & level 2 work for me, from your link.
Latest poll, released Sept. 29, found that a slim majority—52 percent—of California adults support Prop. 64, while 41 percent oppose it. Six percent were undecided, and 1 percent said they won’t vote.
Link https://www.leafly.com/news/politics/data-dive-prop-64-poll-reveals-bikers-love-legalization-and-other-curious-trends/
Article in the LA Times states - California voters will most likely legalize recreational marijuana this November
link - http://www.latimes.com/local/abcarian/la-me-abcarian-pot-initiative-20160819-snap-story.html
California Proposition 64, Marijuana Legalization (2016)
California Proposition 64, the California Marijuana Legalization Initiative, will be on the November 8, 2016, ballot in California as an initiated state statute. Supporters refer to the initiative as the Adult Use of Marijuana Act.
A "yes" vote supports legalizing recreational marijuana and hemp under state law and establishing certain sales and cultivation taxes.
A "no" vote opposes this proposal legalizing recreational marijuana and hemp under state law and establishing certain sales and cultivation taxes.[1]
Initiatives designed to legalize recreational marijuana are on the ballot in five states in 2016, including California. The other four states are Arizona, Maine, Massachusetts, and Nevada
Link https://ballotpedia.org/California_Proposition_64,_Marijuana_Legalization_(2016)
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
OWCP and Cannabis Condoms? remember pfizer! when the blue pill came out?
patent # WO2016098112 A1
NOVEL CONDOM COMPRISING CANNABIS DERIVED COMPOSITIONS FOR ENHANCEMENT OF SEXUAL PLEASURE AND DECREASE OF ERECTILE DYSFUNCTION SYMPTOMS
FIELD OF THE INVENTION
The present invention is in the field of contraceptive and prophylactic devices. More particularly, it pertains to providing condoms made of novel materials comprising cannabis or cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms, and to condoms additives (like lubricants) comprising cannabis or cannabis derived compositions for treatment of the same.
The present invention provides a biocompatible polymer or biocompatible material or composition for forming at least part of the structure of a condom useful for preventing STI's. The biocompatible polymer incorporates cannabis or cannabis derived compositions. The present invention also provides a biocompatible additive for condoms incorporating cannabis or cannabis derived compositions in a carrier or excipient. In addition, the biocompatible polymer or biocompatible additive incorporating cannabis or cannabis derived compositions enhances pleasure during the sexual act. Lastly, the biocompatible polymer or biocompatible additive incorporating cannabis or cannabis derived compositions can be used for the treatment of erectile dysfunction.
link https://www.google.com/patents/WO2016098112A1?cl=en&dq=inassignee:%22One+World+Cannabis+Ltd%22&hl=en&sa=X&ved=0ahUKEwjVyuzX5M_PAhWB6iYKHSDvACkQ6AEIHjAA
OWCP has a Patent on Cannabis Condoms, Anyone remember how much pfizer went up with the blue pill?
NOVEL CONDOM COMPRISING CANNABIS DERIVED COMPOSITIONS FOR ENHANCEMENT OF SEXUAL PLEASURE AND DECREASE OF ERECTILE DYSFUNCTION SYMPTOMS
FIELD OF THE INVENTION
The present invention is in the field of contraceptive and prophylactic devices. More particularly, it pertains to providing condoms made of novel materials comprising cannabis or cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms, and to condoms additives (like lubricants) comprising cannabis or cannabis derived compositions for treatment of the same.
The present invention provides a biocompatible polymer or biocompatible material or composition for forming at least part of the structure of a condom useful for preventing STI's. The biocompatible polymer incorporates cannabis or cannabis derived compositions. The present invention also provides a biocompatible additive for condoms incorporating cannabis or cannabis derived compositions in a carrier or excipient. In addition, the biocompatible polymer or biocompatible additive incorporating cannabis or cannabis derived compositions enhances pleasure during the sexual act. Lastly, the biocompatible polymer or biocompatible additive incorporating cannabis or cannabis derived compositions can be used for the treatment of erectile dysfunction.
link https://www.google.com/patents/WO2016098112A1?cl=en&dq=inassignee:%22One+World+Cannabis+Ltd%22&hl=en&sa=X&ved=0ahUKEwjVyuzX5M_PAhWB6iYKHSDvACkQ6AEIHjAA
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
Should get an update on results soon.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021 - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
UpdateDD on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Links to market value of treatment:
The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
DD on Future growth and value creation of OWCP - Big Money to be made here.
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Multiple myeloma - orphan status designation
NEW YORK (GBI Research) - The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate Compound Annual Growth Rate (CAGR) of 4.6%, says business intelligence provider GBI Research.
link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
-----
A form of bone marrow cancer that accounts for 2% of all cancer deaths. In preliminary studies, the Company demonstrated that some combinations of THC and CBD led to the eradication of 100% of myeloma cells in 60% of the cultured cells within 24 to 48 hours of exposure to the cannabinoid formulation. These early stage in-vitro results may be limited, but they demonstrate significant potential within the market.
Link http://www.baystreet.ca/viewarticle.aspx?id=437873
Psoriasis - marketing of a cannabinoid-based topical cream
The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3%, according to research and consulting firm GlobalData.
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
fibromyalgia - orphan status designation
The treatment market value for fibromyalgia across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
post-traumatic stress disorder ( PTSD )
The annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion, often due to misdiagnosis and under treatment. This includes psychiatric and non-psychiatric medical treatment costs, indirect workplace costs, mortality costs, and prescription drug costs. An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas.
link http://www.ptsdunited.org/ptsd-statistics-2/
Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.
link http://www.prnewswire.com/news-releases/global-post-traumatic-stress-disorder-therapeutics-market-2015-2019-300109175.html
DD on Future growth and value creation of this stock - Big Money to be made here.
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Multiple myeloma - orphan status designation
NEW YORK (GBI Research) - The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate Compound Annual Growth Rate (CAGR) of 4.6%, says business intelligence provider GBI Research.
link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
-----
A form of bone marrow cancer that accounts for 2% of all cancer deaths. In preliminary studies, the Company demonstrated that some combinations of THC and CBD led to the eradication of 100% of myeloma cells in 60% of the cultured cells within 24 to 48 hours of exposure to the cannabinoid formulation. These early stage in-vitro results may be limited, but they demonstrate significant potential within the market.
Link http://www.baystreet.ca/viewarticle.aspx?id=437873
Psoriasis - marketing of a cannabinoid-based topical cream
The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3%, according to research and consulting firm GlobalData.
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
fibromyalgia - orphan status designation
The treatment market value for fibromyalgia across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
post-traumatic stress disorder ( PTSD )
The annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion, often due to misdiagnosis and under treatment. This includes psychiatric and non-psychiatric medical treatment costs, indirect workplace costs, mortality costs, and prescription drug costs. An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas.
link http://www.ptsdunited.org/ptsd-statistics-2/
Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.
link http://www.prnewswire.com/news-releases/global-post-traumatic-stress-disorder-therapeutics-market-2015-2019-300109175.html